

Kishore VI Parsa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1381144/publications.pdf>

Version: 2024-02-01

34
papers

839
citations

471061

17
h-index

500791

28
g-index

35
all docs

35
docs citations

35
times ranked

1311
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of polyethyleneimine polymer in cell culture as attachment factor and lipofection enhancer. <i>BMC Biotechnology</i> , 2004, 4, 23.	1.7	170
2	Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes. <i>Current Drug Targets</i> , 2009, 10, 71-87.	1.0	93
3	The tyrosine kinase Syk promotes phagocytosis of Francisella through the activation of Erk. <i>Molecular Immunology</i> , 2008, 45, 3012-3021.	1.0	48
4	BMRP is a Bcl-2 binding protein that induces apoptosis. <i>Journal of Cellular Biochemistry</i> , 2005, 94, 611-626.	1.2	37
5	Francisella gains a survival advantage within mononuclear phagocytes by suppressing the host IFN γ response. <i>Molecular Immunology</i> , 2008, 45, 3428-3437.	1.0	37
6	Negative Regulators of Toll-like Receptor 4-Mediated Macrophage Inflammatory Response. <i>Current Pharmaceutical Design</i> , 2006, 12, 4143-4153.	0.9	31
7	Novel 1-alkynyl substituted 1,2-dihydroquinoline derivatives from nimesulide (and their 2-oxo) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Letters, 2011, 21, 6573-6576.	1.0	30
8	Pyrrolo[2,3-b]quinoxalines as inhibitors of firefly luciferase: Their Cu-mediated synthesis and evaluation as false positives in a reporter gene assay. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6433-6441.	1.0	28
9	MicroRNA-16 modulates macrophage polarization leading to improved insulin sensitivity in myoblasts. <i>Biochimie</i> , 2015, 119, 16-26.	1.3	24
10	InCl ₃ mediated heteroarylation of indoles and their derivatization via C-H activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis. <i>European Journal of Medicinal Chemistry</i> , 2019, 174, 198-215.	2.6	24
11	Montmorillonite K-10 mediated green synthesis of cyano pyridines: Their evaluation as potential inhibitors of PDE4. <i>European Journal of Medicinal Chemistry</i> , 2012, 48, 265-274.	2.6	23
12	C=C bond formation at C-2 of a quinoline ring: Synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2199-2207.	1.4	23
13	Synthesis of 2H-1,3-benzoxazin-4(3H)-one derivatives containing indole moiety: Their in vitro evaluation against PDE4B. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1166-1171.	1.0	23
14	Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1104-1109.	1.0	22
15	AlCl ₃ induced C-arylation/cyclization in a single pot: a new route to benzofuran fused N-heterocycles of pharmacological interest. <i>Tetrahedron Letters</i> , 2012, 53, 1134-1138.	0.7	21
16	ERK1/2 activated PHLPP1 induces skeletal muscle ER stress through the inhibition of a novel substrate AMPK. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1702-1716.	1.8	21
17	Montmorillonite K-10 catalyzed green synthesis of 2,6-unsubstituted dihydropyridines as potential inhibitors of PDE4. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 395-404.	2.6	18
18	Pd-mediated functionalization of polysubstituted pyrroles: Their evaluation as potential inhibitors of PDE4. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5639-5647.	1.0	17

#	ARTICLE	IF	CITATIONS
19	Design and synthesis of 4-alkynyl pyrazoles as inhibitors of PDE4: A practical access via Pd/Cu catalysis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2480-2487.	1.0	16
20	IFN β enhances IL β production during <i>Francisella</i> infection of human monocytes. <i>FEBS Letters</i> , 2008, 582, 1044-1048.	1.3	13
21	Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 855-869.	2.5	13
22	PHLPP1 promotes neutral lipid accumulation through AMPK/ChREBP-dependent lipid uptake and fatty acid synthesis pathways. <i>IScience</i> , 2022, 25, 103766.	1.9	13
23	In-house made nucleofection buffer for efficient and cost effective transfection of RAW 264.7 macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2017, 487, 247-254.	1.0	11
24	MicroRNA-712 restrains macrophage pro-inflammatory responses by targeting LRRK2 leading to restoration of insulin stimulated glucose uptake by myoblasts. <i>Molecular Immunology</i> , 2017, 82, 1-9.	1.0	11
25	Synthesis of 11,12-dihydro benzo[c]phenanthridines via a Pd-catalyzed unusual construction of isocoumarin ring/FeCl $_3$ -mediated intramolecular arene-allyl cyclization: First identification of a benzo[c]phenanthridine based PDE4 inhibitor. <i>Bioorganic Chemistry</i> , 2020, 97, 103691.	2.0	11
26	PdCl $_2$ -catalyzed synthesis of a new class of isocoumarin derivatives containing aminosulfonyl / aminocarboxamide moiety: First identification of a isocoumarin based PDE4 inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2021, 221, 113514.	2.6	11
27	Conformationally restricted novel pyrazole derivatives: Synthesis of 1,8-disubstituted 5,5-dimethyl-4,5-dihydro-1H-benzo[g]indazoles as a new class of PDE4 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3248-3255.	1.0	10
28	Novel imidazophenoxazine-4-sulfonamides: Their synthesis and evaluation as potential inhibitors of PDE4. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 1952-1963.	1.4	10
29	Deubiquitinase USP12 promotes LPS induced macrophage responses through inhibition of β -catenin. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 69-74.	1.0	10
30	LPS depletes PHLPP levels in macrophages through the inhibition of SP1 dependent transcriptional regulation. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 533-538.	1.0	9
31	Synthesis of N-(3-arylprop-2-ynyl)substituted olanzapine derivatives as potential inhibitors of PDE4B. <i>Tetrahedron Letters</i> , 2014, 55, 3176-3180.	0.7	4
32	PHLPPs: Emerging players in metabolic disorders. <i>Drug Discovery Today</i> , 2022, 27, 103317.	3.2	4
33	Fe(III)-catalyzed regioselective and faster synthesis of isocoumarins with 3-oxoalkyl moiety at C-4: Identification of new inhibitors of PDE4. <i>Bioorganic Chemistry</i> , 2022, 121, 105667.	2.0	3
34	PIMT/TGS1: An evolving metabolic molecular switch with conserved methyl transferase activity. <i>Drug Discovery Today</i> , 2022, , .	3.2	0